AnnJi Pharmaceutical has filed its Phase 3 protocol with the FDA and is moving to activate U.S. sites for ROMA-KD, a global, randomized, double-blind, placebo-controlled trial targeting roughly 200 ambulatory patients with spinal and bulbar muscular atrophy (SBMA, or Kennedy’s disease). The number worth noting is 200: for a disease with a prevalence estimated around 0.46 per 100,000 males in population studies, enrolling that many ambulatory, symptomatic patients globally will likely be the rate-limiting factor in this program’s timeline, not regulatory paperwork.

The drug, AJ201 (rosolutamide), is an oral small molecule designed to clear the pathogenic mutant androgen receptor protein and activate stress-response pathways including Nrf1, Nrf2, and HSF1. AnnJi describes it as a potential first-in-class therapy for SBMA, a claim the FDA has implicitly acknowledged through both Fast Track and Orphan Drug Designations. The Phase 3 design follows a Phase 1/2a readout announced in May 2025, which AnnJi characterized as positive, and was shaped by subsequent regulatory interactions. Approved options for SBMA remain limited to supportive care, so the bar for demonstrating meaningful clinical benefit is scientifically clear even if it is not yet defined by precedent.

The trial’s primary population is ambulatory patients with symptomatic SBMA, a deliberate eligibility choice that reflects both clinical practicality and a desire to capture functional endpoints before disease progression removes them. AnnJi has also established an SBMA Patient and Care Partner Advisory Council, built in collaboration with the Kennedy’s Disease Association, to inform study design and patient-facing materials. The council operates independently of the trial itself and has no bearing on enrollment eligibility, a structural choice that keeps community input from creating conflicts at sites.

Because SBMA is X-linked and frequently misdiagnosed as ALS, the trial’s ability to identify and screen eligible patients will depend heavily on referring neurologist awareness. Site activation speed in the U.S. is the concrete variable to watch: how quickly AnnJi can open enough centers to realistically recruit 200 patients globally will determine whether this program produces a regulatory package on any near-term schedule.

Source link: https://www.prnewswire.com/news-releases/annji-pharmaceutical-advances-aj201-into-pivotal-phase-3-roma-kd-trial-for-spinal-and-bulbar-muscular-atrophy-sbma-302897931.html

AJ201: the facts in one place

  • Also written: Rosolutamide, JM17
  • Sponsor: AnnJi Pharmaceutical Co., Ltd.
  • Mechanism: Promotes clearance of pathogenic mutant androgen receptor (mAR) protein and activates cellular stress-response pathways including Nrf1, Nrf2, and HSF1, reducing cellular toxicity, oxidative stress, and neuroinflammation
  • Indication studied: Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy’s Disease
  • Phase: Phase 3 (ROMA-KD trial); prior Phase 1/2a completed
  • Enrollment: 200
  • Headline result: Phase 1/2a demonstrated clinically meaningful improvements in physical function, reductions in serum creatine kinase and myoglobin levels, and significant decrease in mutant AR protein in muscle biopsies
  • Registry identifier: NCT05517603
  • Current status: Pivotal Phase 3 trial (ROMA-KD) cleared by FDA around October 3, 2026; U.S. sites being activated; holds FDA Orphan Drug Designation, EMA Orphan Drug Designation, and FDA Fast Track Designation
  • FDA Fast Track Designation granted: October 2025
  • FDA clearance to proceed with Phase 3 ROMA-KD trial: October 3, 2026
  • Press release announcing Phase 3 ROMA-KD advancement: October 5, 2026
  • FDA Fast Track Designation announcement: October 22-29, 2025
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.